![](/img/cover-not-exists.png)
Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
Quintyne, K.I., Woulfe, B., Dee, A., Gupta, R.Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw377.11
Date:
October, 2016
File:
PDF, 33 KB
english, 2016